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To the Editor,
Rituximab, the monoclonal antibody directed against
CD20, represents ideal treatment of both membranous
nephropathy (MN) and demyelinating neuropathy associ-
ated with antibodies to myelin-associated glycoprotein
(MAG) [1, 2]. Clinical efficacy, safety, and modulating
effects on normal and malignant pre-B and mature B cells
have been reported [1, 2]. We encountered a 63-year-old
woman who experienced acute onset of demyelinating
polyneuropathy (AIDP) after rituximab infusions to treat
her nephrotic syndrome (NS) [1]. This patient presented
5 month history of peripheral swelling and microscopic
haematuria. Laboratory tests showed normal creatinine
(0.8 mg/dl), heavy proteinuria (6 g/daily), and negative
screening for secondary causes of MN [1]. Renal biopsy
showed diffuse thickening of glomerular capillary base-
ment membrane with basement membrane spikes and
subepithelial granular deposits of IgG and C3 on
immunofluorescence. She had circulating anti-phospholi-
pase A2 receptor (PLA2R) antibodies [1]. Patient received
intravenous methylprednisolone (10 mg/kg of bw daily for
3 days) followed by tapering oral prednisone and
cyclophosphamide (100 mg daily). Due to proteinuria
exceeding 5 g/daily, 5 months later, patient was started on
6 month infusions of rituximab (375 mg/m2) with clinical
improvement. Five years later, because of NS relapse, a
course of rituximab was started in a dosage of 375 mg/m2.
Ten days after fourth infusion, patient exhibited acute
arthralgias, burning numbness in feet, which involved both
legs and fingertips, and gait imbalance. After few hours,
she developed hand and lower extremity distal muscle
weakness, graded 3/5 on Medical Research Council Scale
(MRC). Electrophysiology showed dispersed tibial and
peroneal F-waves. Normal laboratory studies included
rheumatological, virological, microbiological, neoplastic
tests, and searches for anti-ganglioside antibodies in serum
[3, 4]. Clinical signs spontaneously regressed within
2 weeks. In the following 6 years, patient had no neuro-
logical symptoms. In February 2016, due to relapse of her
NS, a rituximab course was planed. Seven days after a
single infusion of 375 mg/m2, patient acutely developed
ascending numbness and paraesthesias in hands and feet.
On examination, cranial nerves and sensory testing were
intact; there were 3/5 MRC weakness in upper extremities,
2/5 in the lower, deep areflexia, ataxic gait. Electrophysi-
ology showed motor demyelinating neuropathy with slo-
wed velocity (within 38 and 40 m/s) in all tested nerves,
tibial, ulnar motor conduction blocks (CBs) [2], and normal
sensory responses. Spinal tap was denied. Rituximab was
halted. At 8 week follow-up, there was no residual weak-
ness neither detectable CBs.
Our patient exhibited acute onset of demyelinating
motor neuropathy (AIDP) that presented 6 years after NS
due to MN. The long time interval between NS and our
patient AIDP raised the possibility of coincidental associ-
ation or of worsening of a pre-existing subclinical chronic
neuropathy. This possibility was excluded as our patient
had no prior neurological symptoms or signs. Furthermore,
she denied antecedent infections. We know that AIDP are
caused by aberrant autoimmune response damaging
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peripheral nerves and nerve roots by molecular mimicry
mechanism, which may trigger, after infections, production
of cross-reactive autoantibodies to gangliosides found in
serum of half of AIDP patients. Such autoantibodies were
absent in our subject. Moreover, AIDP rarely develops in
patients who suffer from other autoimmune conditions [5].
We believe that the neuropathy of this patient should be
classified as drug induced because of temporal association,
lack of alternative explanation, and regression after inter-
ruption of rituximab without additional specific therapies.
No other medications could be incriminated. The recur-
rence of neurological status after rituximab is strong
argument for relation between neuropathy and treatment
administered [3–5]. Rituximab induced Guillain–Barre´
syndrome in patient with idiopathic thrombocytopenic
purpura [3] and a paradoxical worsening of anti-MAG
polyneuropathy [4, 5]. Rituximab might rarely produce
precipitous onset of reversible demyelination, as docu-
mented in our case by serial studies [3, 5]; nevertheless, it
represents promising treatment for neuropathies associated
with B-cell dyscrasias [2]. Rituximab specifically elimi-
nates CD20 and their precursors; however, despite inhibi-
tion of CD20 cells, other pathogenic antibodies might be
produced, either by CD20 cells at maturative stages or by
different B-cell sub populations [2–4]. Some authors
speculated that worsening could be the result of a specific
autoimmune response induced by rituximab due to dis-
ruption of idiotype–anti-idiotype network and promotion of
autoantibodies by proinflammatory cytokine interleukin-6,
which demonstrated to be significantly elevated [5]. It is
not clear how best to avoid or clinically predict this rare
complication; measures might include pretreatment with
corticosteroids, as has been proposed in Waldenstro¨m
disease patients to prevent hyperviscosity [3, 5].
Given that one does not condemn a potentially important
therapy based on isolated reports [1, 2, 5]. The current case
provides emphasis that new therapies require close clinical
monitoring and strict indications.
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